Media Contact:
Nat Wood
410-507-7898
NatWood@rational360.com

GLOBAL ALZHEIMER’S PLATFORM FOUNDATION

Statement on the National Strategy for Recruitment and Participation in Alzheimer’s Disease Clinical Research

National Strategy Released by National Institute on Aging Today

WASHINGTON, D.C. (October 19, 2018) – Statement on the National Strategy for Recruitment and Participation in Alzheimer’s Disease Clinical Research from John Dwyer, President of the Global Alzheimer’s Platform Foundation and member of the Steering Committee for the national strategy:

“I would like to thank the National Institute on Aging for its thoughtful work on the national strategy. More effective recruitment means faster trials and getting approved therapies to market years sooner. The Global Alzheimer’s Platform Foundation is pleased to join in this effort by building a better research infrastructure through GAP-NET, its network of leading academic and private research centers; forging partnerships with healthcare professionals to increase the participation of African Americans and Latinos; and breaking down barriers to faster, more efficient clinical trials.

About Global Alzheimer’s Platform Foundation (GAP)

The Global Alzheimer’s Platform Foundation (GAP) is a patient-centric nonprofit dedicated to speeding the delivery of innovative medicines to those in need by reducing the time and cost of Alzheimer’s disease clinical trials. In collaboration with other foundations, research centers and industry, GAP established GAP-Net, a growing network of more than 65 academic and private Alzheimer’s disease research centers. GAP-Net sites share data, best practices, use of a central Institutional Review Board and common clinical trial contracts. GAP and GAP-Net are committed to disrupting clinical trial recruitment, study conduct processes and to reducing clinical testing cycles by up to two years. GAP is a 501c3 organization. To learn more about GAP, please visit: www.globalalzplatform.org.